## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 6.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($365.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Waters Corp stock: quiet consolidation, cautious optimism and a year of disciplined rebuilding**
- Source: AD HOC NEWS | 20251231T173617 | Somewhat-Bullish | Relevance: 100%
- Waters Corp (WAT) stock is currently in a quiet consolidation phase after a volatile fourth quarter, showing modest gains and low volatility. Analysts are cautiously optimistic, maintaining "Hold" to "Buy" ratings, as the company focuses on high-value biopharma and QA/QC workflows, navigating macro headwinds. Despite a challenging year for capital spending, long-term investors holding WAT have seen a modest positive return, reflecting the company's resilience and a strategic shift towards recurring revenue streams.

**2. Waters Corp stock: quiet consolidation, cautious optimism and a year of disciplined rebuilding**
- Source: AD HOC NEWS | 20251231T170816 | Somewhat-Bullish | Relevance: 100%
- Waters Corp (WAT) stock has entered a quiet consolidation phase after a volatile quarter, showing modest gains and low volatility. Analysts maintain neutral to positive views, emphasizing disciplined investment in high-value biopharma and QA/QC workflows, with price targets modestly above current trading. The company's strategy focuses on integrating core hardware with software, services, and data analytics to smooth revenue fluctuations and evolve into a resilient platform provider, suggesting a potential for sturdier valuation multiples if execution remains strong.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.3x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 6.29 signals overvaluation risk, limited margin of safety. Forward P/E 26.7x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.7B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.29 |
| Forward P/E | 26.7 |
| Current P/E | 29.1 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-1.24), momentum weakening. RSI neutral at 49. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.55% (CS: 47) | Neutral |
| RSI_14 | 48.8 | Neutral |
| MACD Histogram | -1.24 | Bearish |
| vs SMA20 | 0.991x | Below |
| vs SMA50 | 1.007x | Above |
| vs SMA200 | 1.126x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $381.96
- **Stop Loss:** $365.86 (4.2% risk)
- **Target:** $398.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 89
- **Position Value:** $33,994.44
- **Portfolio %:** 33.99%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*